m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT00470
 [1], [2], [3]
RNA modification MIR149 MIR149 METTL1 Methylation : modification sites Indirect Enhancement m6A modification CXCL12 CXCL12 METTL3 Methylation : m6A sites
m6A Modification:
m6A Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
m6A Target Stromal cell-derived factor 1 (CXCL12)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type RNA modification (RNAMod)  >> N7-methylguanosine (m7G)
Epigenetic Regulator Methyltransferase-like protein 1 (METTL1) WRITER View Details
Regulated Target MicroRNA 149 (MIR149) View Details
Crosstalk Relationship m7G  →  m6A Enhancement
Crosstalk Mechanism RNA modification indirectly impacts m6A modification through downstream signaling pathways
Crosstalk Summary METTL1 interacts with MicroRNA 149 (MIR149), increasing it's m7G level and promoting its physical interaction with Stromal cell-derived factor 1 (CXCL12), which was regulated by METTL3-mediated m6A modification.
In-vitro Model
 SW480 Colon adenocarcinoma Homo sapiens CVCL_0546
SW620 Colon adenocarcinoma Homo sapiens CVCL_0547
HCT 116 Colon carcinoma Homo sapiens CVCL_0291
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Stromal cell-derived factor 1 (CXCL12) 5 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name MyoCell SDF-1 Phase 3 [4]
Synonyms
Autologous skeletal myoblast therapy (SDF-1, cardiovascular disease), Bioheart
    Click to Show/Hide
MOA Modulator
External Link
TTD: D0DR4W
 Compound Name Dociparstat sodium Phase 3 [5]
Synonyms
DSTAT
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D5VRX2
 Compound Name SDF-1 Phase 2 [6]
Synonyms
JVS-100
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D07YLO
 Compound Name NOX-A12 Phase 1 [7]
Synonyms
Ocular antineovascularisation agent/angiogenesis inhibitor (diabetic retinopathy/AMD), NOXXON; SDF-1 inhbitor (spiegelmer, stem cell transplantation), NOXXON; CXCL12 inhibitor (spiegelmer, diabetic retinopathy/AMD/stem cell transplantation), Noxxon
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0D8MG
 Compound Name REC-02 Phase 1 [8]
MOA Modulator
External Link
TTD: D0K6NW
References
Ref 1 Hypoxia Promotes Vascular Smooth Muscle Cell (VSMC) Differentiation of Adipose-Derived Stem Cell (ADSC) by Regulating Mettl3 and Paracrine Factors. Stem Cells Int. 2020 Feb 20;2020:2830565. doi: 10.1155/2020/2830565. eCollection 2020.
Ref 2 Overexpressed methyltransferase-like 1 (METTL1) increased chemosensitivity of colon cancer cells to cisplatin by regulating miR-149-3p/S100A4/p53 axis. Aging (Albany NY). 2019 Dec 20;11(24):12328-12344. doi: 10.18632/aging.102575. Epub 2019 Dec 20.
Ref 3 Hypermethylation of microRNA-149 activates SDF-1/CXCR4 to promote osteogenic differentiation of mesenchymal stem cells. J Cell Physiol. 2019 Dec;234(12):23485-23494. doi: 10.1002/jcp.28917. Epub 2019 Jun 17.
Ref 4 Stromal cell-derived factor-1 (SDF-1): homing factor for engineered regenerative medicine. Expert Opin Biol Ther. 2011 Feb;11(2):189-97.
Ref 5 Clinical pipeline report, company report or official report of Chimerix.
Ref 6 SDF-1 in myocardial repair. Gene Ther. 2012 Jun;19(6):583-7.
Ref 7 SDF-1/CXCR4/CXCR7 is pivotal for vascular smooth muscle cell proliferation and chronic allograft vasculopathy. Transpl Int. 2015 Dec;28(12):1426-35.
Ref 8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)